EyePoint appoints Dr. Reginald Sanders, retina specialist and former ASRS president, to board

EyePoint, Inc.

Board expanded to nine members; Dr. Sanders appointed effective Jan 8, 2025.
Receives $45,000 annual cash retainer and option for 80,000 shares vesting over 3 years.
Sanders brings expertise as ex-president of American Society of Retina Specialists and PI for Lucentis.
He served as president and managing partner of Retina Group of Washington, largest U.S. retina practice.
Appointment coincides with Phase 3 trials for wet AMD and positive interim Phase 2 DME data.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Reginald Sanders

Director

EYPT · EyePoint, Inc.

Effective: 2025-01-08
Filed: January 8, 2025, 6:59 PM ET

appointed Dr. Reginald Sanders, M.D. to fill the vacancy on the Board, effective January 8, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Reginald Sanders was appointed as Director at EyePoint, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Dr. Reginald Sanders, M.D. to fill the vacancy on the Board, effective January 8, 2025.

View on SEC.gov

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-003280

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.